托法替尼

托法替尼（CAS 477600-75-2）的公开数据库记录，列此仅供独立核对。

危险化学品分类与危害说明

物理形态与操作说明

• White crystalline solid. MP: 199-206 °C /Tofacitinib monocitrate/
• Stable under recommended storage conditions. /Tofacitinib citrate/
• Specific optical rotation: +10.4 deg at 25 °C/D (c = 0.64 in methanol)
• pKa1 = 8.46 (cyano); pKa2 = 13.56 (secondary amine)
• Oral: Tablets, film-coated, 5 mg (of tofacitinib), Xeljanz (Pfizer).

公开数据库收录的理化数据

这个物质在各数据库里的编号

数据库记载的用途

• Preparation (unspecified stereo): T. A. Blumenkopf et al., World Intellectual Property Organization patent 0142246; eidem, United States of America patent 7265221 (2001, 2007 both to Pfizer).
• Tofacitinib is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease. Tofacitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy, but has yet to be linked to cases of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Milk, Human; Antirheumatic Agents; Enzyme Inhibitors; Janus Kinase Inhibitors; JAK Inhibitors; Signal Transduction Inhibitors; Protein Kinase Inhibitors
• Xeljanz (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). /Included in US product label/
• /BOXED WARNING/ MALIGNANCIES. Lymphoma and other malignancies have been observed in patients treated with Xeljanz. Epstein Barr Virus-associated post-transplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with Xeljanz and concomitant immunosuppressive medications
• Patients receiving tofacitinib are at increased risk of developing serious infections that may require hospitalization or result in death. Opportunistic infections caused by bacterial, mycobacterial, invasive fungal, viral, or other opportunistic organisms-including cryptococcosis, pneumocystosis, tuberculosis and other mycobacterial infections, esophageal candidiasis, multidermatomal herpes zoster, cytomegalovirus infection, and BK virus infection-have been reported in patients with rheumatoid arthritis receiving

它在各数据库里的别名

Tofacitinib; 477600-75-2; Tasocitinib; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; Cp-690 free base; tofacitinibum; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; CP690550; 87LA6FU830; CP-690550 FREE BASE; CP-690,550 FREE BASE; CP690,550; CP-690-550; CHEBI:71200

计算机算出的分子描述符

数据库摘要

Tofacitinib · CAS 477600-75-2 · C16H20N6O. UNII 87LA6FU830. LogP: 1.808.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。